Published in final edited form as:

Vaccine. 2012 August 3; 30(36): 5407–5416. doi:10.1016/j.vaccine.2012.06.009.

Randomized Clinical Trial Of Immunogenicity And Safety Of A Recombinant H1N1/2009 Pandemic Influenza Vaccine Containing Advax™ Polysaccharide Adjuvant

David L. Gordon, MBBS, FRACP, PhD¹, Dimitar Sajkov, MD, FRACP, PhD, FCCP², Richard J. Woodman, PhD⁴, Yoshikazu Honda-Okubo, PhD⁶, Manon M.J. Cox, PhD⁵, Susanne Heinzel, PhD⁶, and Nikolai Petrovsky, MBBS, FRACP, PhD^{2,3,6}

David L. Gordon: d.gordon@flinders.edu.au; Dimitar Sajkov: dimitar.sajkov@health.sa.gov.au; Richard J. Woodman: richard.woodman@flinders.edu.au; Yoshikazu Honda-Okubo: Yoshikazu.Honda@health.sa.gov.au; Manon M.J. Cox: Manon.Cox@ProteinSciences.com; Susanne Heinzel: heinzel@wehi.edu.au; Nikolai Petrovsky: nikolai.petrovsky@flinders.edu.au

¹Department of Microbiology and Infectious Diseases, Flinders Medical Centre and Flinders University, Adelaide, Australia 5042

²Australian Respiratory and Sleep Medicine Institute, Flinders Medical Centre and Flinders University, Adelaide, Australia 5042

³Department of Endocrinology, Flinders Medical Centre and Flinders University, Adelaide, Australia 5042

⁴Discipline of General Practice, Flinders University

⁵Protein Sciences Corporation, Meriden, CT, USA

⁶Vaxine Pty Ltd, Flinders Medical Centre, Adelaide, SA, Australia, 5042

© 2012 Elsevier Ltd. All rights reserved.

Corresponding author: Prof. Nikolai Petrovsky, Endocrinology Dept, Flinders Medical Centre, Bedford Park, SA 5042, AUSTRALIA, nikolai.petrovsky@flinders.edu.au, Ph +61 8 8204 4572, Fax +61 8 8204 5987.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CONFLICT STATEMENT

NP and YH are associated with Vaxine Pty Ltd, which owns Advax™ adjuvant. MC is associated with Protein Sciences Corporation, which owns Flublok®. DLG, DS, RJW, SH declared no conflicts

Author contributions: Drs Gordon, Sajkov, Cox and Petrovsky participated in conception of the trial, protocol development and amendment, and study planning and implementation. Dr Gordon had responsibility for ethics submission. Drs Gordon and Petrovsky wrote the initial draft of the manuscript. All authors had full access to the complete data set and reviewed and edited multiple drafts of the manuscript. Dr Gordon reviewed all adverse events and assessed causality, blinded to treatment. Drs Honda-Okubo and Heinzel managed laboratory setup and sample processing and interpretation of results. Dr Woodman analysed the data set, prepared tables and performed all statistical analysis. Dr Heinzel contributed to study planning and implementation, vaccine distribution, sample collection, collation and analysis of the dataset. All authors have seen and approved the final version of the manuscript.

Other contributors: We thank Dr. Nancy Cox (Centers for Disease Control and Prevention, Atlanta, GA) and Dr. Jesse Goodman (US Food and Drug Administration, Rockville, MD) for the expedited availability of the novel H1N1 virus strain. We thank the clinical trial coordinators and research staff including Sharen Pringle, Brigit McAteer, Kylie Bragg, Lynda Borg, Susan Virgin, Lyndall Stone, Frances Kissajukian and Melody Vrakking for their expert assistance. We thank all the study participants for their voluntary participation in the study. Reference ferret sera to H1N1/A/California/07/2009 was provided by the Biodefense and Emerging Infections (BEI) Research Resources Repository, NIH. Development of Advax™ adjuvant was supported by Contracts U01-AI061142 and HHSN272200800039C from the National Institutes of Health, National Institute of Allergy and Infectious Diseases. This publication's contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.

Abstract

Background—Timely vaccine supply is critical during influenza pandemics. A recombinant hemagglutinin (rHA)-based vaccine could overcome production hurdles of egg-based vaccines but has never previously been tested in a real-life pandemic setting. The primary aim was to determine the efficacy of a recombinant pandemic vaccine and whether its immunogenicity could be enhanced by a novel polysaccharide adjuvant (Advax™).

Methods—281 adults aged 18–70 years were recruited in a randomized, subject and observer blinded, parallel-group study of rHA H1N1/2009 vaccine with or without adjuvant. Immunizations were at 0 and 3 weeks with rHA 3, 11 or 45 ug. Serology and safety was followed for 6 months.

Results—At baseline, only 9.1% of subjects (95% CI = 6.0 – 13.2) had seroprotective H1N1/2009 titers. Seroconversion rates varied by rHA dose, presence of adjuvant, subject age and number of immunizations. Eighty percent (95% CI = 52 – 96) of 18 – 49 year olds who received rHA 45ug with adjuvant were seroprotected at week 3, representing a 11.1-fold increase in antibody titers from baseline. Advax™ adjuvant increased seroprotection rates by 1.9 times after the first, and 2.5 times after the second, immunization when compared to rHA alone. Seroprotection was sustained at 26 weeks and the vaccine was well tolerated with no safety issues.

Conclusions—The study confirmed the ability to design, manufacture, and release a recombinant vaccine within a short time from the start of an actual influenza pandemic. Advax™ adjuvant significantly enhanced rHA immunogenicity.

Keywords

Vaccine; Influenza; Pandemic; Adjuvant; Recombinant; Antigen; Advax™

INTRODUCTION

The 2009 H1N1 influenza pandemic was associated with a rapid upsurge in hospital and intensive care unit admissions for severe respiratory illness, characterized by hypoxemia, multi-organ failure and prolonged mechanical ventilation requirements[1,5]. This pandemic, the first in over 30 years, highlighted the need for faster and more efficient pandemic vaccine production. Traditional vaccines which rely on cultivation of adapted influenza virus in eggs take 3–4 months to establish, with yields dependent on the selected seed strain[6]. Early in the 2009 pandemic, the initial influenza A/H1N1/California/04/2009 strain distributed by Centre for Disease Control (CDC) provided unsatisfactory yields, requiring selection of a higher-yield strain (A/H1N1/California/07/2009), thereby delaying vaccine availability[7, 8]. Furthermore, egg supply is vulnerable to supply disruptions and such vaccines may not be suitable for children with severe egg allergies[9, 10]. Whilst this problem has been addressed by the recent development of large-scale facilities for mammalian cell culture of influenza virus and several cell-culture inactivated vaccines now licensed [11, 12], an alternative vaccine substrate is recombinant hemagglutinin (rHA). HA is the dominant target of protective neutralising antibodies after natural infection or vaccination[13, 14]. The predictability and speed of recombinant protein production makes this an attractive technology for pandemic vaccines, and in response to the Public Health Emergency Medical Countermeasures Enterprise Review the US government has awarded large contracts to several companies to produce recombinant influenza vaccines[15]. Insect cell-derived rHA produced using the baculovirus expression system has been in clinical testing for a number of years as an alternative to inactivated influenza virus vaccines. The efficacy of rHA protection against seasonal influenza was confirmed in a study of 4,648 subjects[16, 17].

In pandemic studies, rHA protected birds against lethal infection with H5 or H7 strains[18] although only low levels of seroprotection were achieved in humans administered rHA5[19], indicating the need for an adjuvant. Furthermore, given that antigen manufacture is a major limiting factor in vaccine supply, adjuvant-based dose-sparing strategies are a major pandemic priority. Advax™ is a novel polysaccharide adjuvant based on particles of semi-crystalline delta inulin [20], which was developed through the Adjuvant Development Program of the National Institutes of Health. Advax™ enhances vaccine immunogenicity and protection in a range of animal models including Japanese encephalitis[21], HIV[22] and avian H5N1 influenza[23]. Although its exact mechanism of action has yet to be determined, Advax™ particles bind directly to human monocytes and enhance their co-stimulatory function[20]. In an influenza challenge study, Advax™ adjuvant significantly enhanced H5N1 vaccine protection, with 100% survival of ferrets receiving adjuvanted vaccine versus only 66% survival with standard H5N1 vaccine[23]. Advax™ adjuvant significantly reduced neurological disease and H5N1 viral shedding while providing over 3-fold antigen dose-sparing[23]. The H1N1/2009 outbreak provided the first opportunity to test the speed and utility of the rHA approach in a real pandemic setting. We report here the findings of a clinical study performed on the first rHA vaccine to be developed during an actual pandemic. The study addressed two main questions: first, whether it is possible to design, manufacture and release a recombinant vaccine within 12 weeks of identification of a new pandemic influenza strain and, second, whether Advax™ adjuvant could improve the immunogenicity of the recombinant antigen.

METHODS

Vaccine Composition

Recombinant HA cloned from H1N1/A/California/04/2009 (Source: CDC ID number 2009712047; Passage 1 MDCK cells) was supplied by Protein Sciences Corporation (PSC), Meriden, USA. The HA gene was cloned from influenza viral RNA as a template in reverse transcriptase PCR reactions (RT-PCR) to generate cDNA which was cloned into a baculovirus transfer vector and then used to transfect *Spodoptera frugiperda* Sf9 insect cells using calcium phosphate precipitation with linearized *Autographa californica* nucleopolyhedrovirus (AcMNPV) genomic DNA and the baculovirus transfer plasmid containing the HA gene[24]. Recombinant virus stock was expanded and added to a bioreactor at a concentration of 1.0 plaque forming unit (PFU)/cell equivalent to 2% (v/v) and incubated at 28° C for 48–72 hours. Infected cells were then removed from the bioreactor(s), separated from the culture media by centrifugation, solubilized using non-ionic detergent and rHA purified by depth filtration, ion-exchange, cation exchange, hydrophobic interaction column, Q-membrane and finally ultrafiltration[24]. Single-dose vials of Advax™ adjuvant containing delta inulin 20 mg in 0.2mls of bicarbonate buffer were supplied by Vaxine Pty Ltd, Adelaide, Australia. Advax™ adjuvant was mixed with the antigen at the bedside immediately prior to injection.

Study Design, Subjects and Study Procedures

A randomized, subject and observer blinded, parallel-group trial was commenced in July 2009 in Adelaide, Australia, to assess safety and immunogenicity of a novel pandemic rHA vaccine in adults aged 18–70 years. The study was approved by the Flinders Clinical Research Ethics Committee. Exclusions included pregnancy, immunosuppressive therapy, oral corticosteroids, HIV infection, or a history of drug or alcohol abuse. Subjects were randomized to 1 of 6 groups to receive rHA (3, 11 or 45ug) +/- Advax™ adjuvant. Randomization was stratified by age; with 18–45 and 46–70 groups. On day 0 signed informed consent was obtained, venesection performed for baseline serology and the first vaccine dose administered by intramuscular injection of ~0.5 mls into the non-dominant

deltoid muscle. At 3 weeks, follow-up bloods were obtained and the second vaccine dose administered. Follow up bloods were taken at 3 weeks and 5 months post the second immunization.

Safety Assessments

Solicited local and systemic reactions were collected with a 7-day memory aid. Serious adverse events were collected throughout the study period. Causality of adverse events was assessed by a blinded Investigator (DLG).

Hemagglutination inhibition assay

Antibody titers were measured by hemagglutination inhibition (HI) assay with guinea pig RBC, as previously described [25], using HA from a South Australian H1N1/2009 virus isolate (SF3). The titer was expressed as the reciprocal of the highest serum dilution inhibiting hemagglutination. Assays included reference ferret hyperimmune sera to A/California/07/2009 (BEI No. NR-15429, NIH).

Statistical Analysis

The three co-primary efficacy endpoints were seroprotection (HI titer 40), seroconversion (4-fold increase and HI titer 40), and fold increase in geometric mean titer (GMT). Data analysis was performed with Stata software (StataCorp, version 11.0). Baseline characteristics were compared using t-tests, chi-square, or ANOVA. Exact binomial confidence intervals were reported for all proportional end points. Reported p-values are two-sided, with no adjustment for multiple testing; $p \leq 0.05$ was considered significant. Geometric mean (GMT) and 95% confidence intervals were computed by taking the exponent of the mean and of the lower and upper limits of the 95% confidence intervals of the log_e-transformed titers. Generalized linear models assessed effects of dose, adjuvant and age on seroprotection and seroconversion rates and GMT. The identity link function was used to assess GMT changes after transformation of HI titer. The logit link function was used to assess effects on seroprotection and seroconversion between visits.

RESULTS

Study Population

281 subjects were enrolled, randomised, had baseline serology and received the first vaccine dose. This group was included in the safety analysis. All subjects in whom follow-up blood samples were obtained at relevant time points after immunization were included in the efficacy analyses. Baseline characteristics of the efficacy population who completed the first immunization and 3 week immunogenicity testing (n=274) are shown in Table 1. Subjects were predominantly Caucasian (96.4%), median age was 52 years, 73% were overweight or obese, 54.7% had chronic disease and 71.2% had received the 2009 seasonal trivalent influenza vaccine. There were no significant differences in baseline characteristics between study groups. A total of 25 subjects (8.9%) withdrew or were lost to follow-up during the study, the majority (n=15) between Visit 3 and Visit 4 (Figure 1). Attempts were made to contact all subjects to ascertain the reason for withdrawal, with the majority stating lack of time to attend the scheduled follow-up visit as the reason. No withdrawals were reported due to adverse events.

Serology at Baseline

At baseline, just 9.1% (95% CI 6.0 – 13.2) of subjects had H1N1/2009 HI titers ≥ 40 , suggesting low prevailing levels of virus exposure at the time of study commencement

(Table 2A). There was no difference in baseline H1N1/2009 seropositivity or GMT between groups and there was no evidence of an effect of age on baseline GMT values.

Timelines of Vaccine Production

The development of a rHA vaccine against the newly identified 2009 H1N1 strain commenced on April 29, 2009 when Protein Sciences Corporation received an isolate of A/California/04/2009 from the Center for Disease Control in Atlanta. By mid-June 2009, just six weeks later, the first batch of rHA was ready for release testing. GMP rHA was supplied to the site in single dose vials, with recoverable antigen in the vials of 3, 11 or 45 ug rHA as determined by bicinchoninic acid (BCA) assay, adjusted for product purity. The first clinical dose of vaccine was administered on 18 July 2009. Production of rHA was undertaken in a 600L fermenter with a working volume of 460L and a run rate of one batch per 5 days. This yielded 15mg/L of purified rHA protein. At the current scale, 150,000 rHA vaccine doses (of 45mcg) can be produced every 5 days. Plans are ongoing to enable scale up of the process to a 10,000L bioreactor that would allow production of >2 million rHA doses of 45mcg every 5 days.

Serological Response to the First Immunization

Three weeks after a single rHA immunization, the highest responders were the 18–49 year old group who received rHA 45ug with Advax™ adjuvant; with a seroprotection rate of 80.0%; (95% CI: 51.9 – 95.7), seroconversion 73.3%; (95% CI: 44.9 – 92.2), and GMT fold increase from baseline of 11.1 (95% CI: 4.6 – 26.4). At the other end of the spectrum, the lowest responding group were subjects aged over 50 years who received rHA 3ug without adjuvant; with a seroprotection rate of 25.0% (95% CI: 9.8–46.7); seroconversion 20.8% (7.1–42.2); and GMT fold increase 1.5 (1.1–2.0). Hence, response rates varied according to rHA dose, presence of adjuvant and subject age (Tables 2A, 2B). The lower responses in older subjects after the first immunization were significantly improved by higher antigen dose and addition of adjuvant (Tables 2A, 2B).

The data was analysed in accordance with the European Union Committee for Medicinal Products for Human Use (CHMP) criteria for influenza vaccines; these require the HI response for adults 18–60 years old to achieve seroprotection 70%, seroconversion 40%, and GMT fold rise 2.5, and for those over 60 years seroprotection 60%, seroconversion 30%, and GMT fold rise 2.0. By these criteria, for the group aged 18–60 years, 11ug rHA +Advax™ passed on 1/3 CHMP criteria, and both 45ug rHA alone and 45ug rHA +Advax™ passed on 2/3 CHMP criteria (Table 2C). For the group aged >60 years, only 45ug rHA +Advax™ passed on 2/3 CHMP criteria (Table 2D).

Serological Response to the Second Immunization

Three weeks after the second immunization there was an overall 1.2-fold (95% CI 1.1–1.3) increase in GMT over the response to the first immunization (Table 3A). The antibody response to the second immunization was again dependent on rHA dose, adjuvant and age (Tables 3A, 3B). Overall, subjects receiving Advax™ adjuvant had 2.5-fold higher odds of achieving seroprotection (95% CI 1.5 – 4.2, $p = 0.001$) and 2.3-fold higher odds of seroconversion (95% CI 1.4 – 3.8, $p = 0.002$) after the second immunization, when compared to subjects receiving rHA alone (Table 3B).

Persistence of Vaccine Response

Pandemic strains may recirculate for several years, making the durability of vaccine-induced protection an important consideration. Seroconversion and seroprotection rates were not significantly reduced at final follow up (Table 4A). Seroprotection rates remained highest

(80.0%; 95% CI 51.9 – 95.7) in the 18 – 49 year old group who had received rHA 45ug with Advax™ adjuvant (Table 4B). Groups who received Advax™ had a 1.5-fold greater GMT increase (95% CI 1.2 – 1.8, $p < 0.001$), 3-fold higher seroprotection (95% CI 1.7 – 5.2, $p < 0.001$) and 2.7-fold higher seroconversion (95% CI 1.6 – 4.6, $p < 0.001$) at 5 months, when compared to subjects who received rHA alone (Table 4B). Late seroconversion may be useful as a marker of clinical virus exposure. Late seroconversion occurring between 6 week and 26 was therefore assessed as a surrogate measure of H1N1/2009 exposure. Overall, a low rate of late seroconversion (10/256; 3.9%) was observed across all study groups; rHA 3ug (0/42; 0.0%), rHA 11ug (1/43; 2.3%), rHA 45ug (2/44; 4.5%), rHA 3ug +Advax™ (4/43; 9.3%), rHA 11ug +Advax™ (1/43; 2.3%), and rHA 45ug +Advax™ (2/41; 4.9%).

Effect of H1N1/2009 Immunization on Immunity to Seasonal H1N1 Strains

The effect of immunization on development of cross-protective antibodies against the co-circulating seasonal influenza strain A/Brisbane/59/2007 was assessed. At baseline 114 (42%) of subjects were seronegative to A/Brisbane/59/2007. Administration of the H1N1/2009 vaccine induced seroconversion (6/114; 5%) in a small proportion of subjects initially seronegative to A/Brisbane/59/2007. In univariate analysis, there was a significant effect of age on the A/Brisbane/59/2007 response to H1N1/2009 immunization (χ^2 ; $p = 0.006$).

Vaccine Tolerability and Safety

Frequencies of solicited local and systemic reactions in the 7 days following each immunization were compared between groups. Overall, rHA alone or with Advax™ adjuvant was well tolerated. Solicited local reactions in the first 7 days following the first immunization were reported by 26.1% of subjects. The most common local reaction was injection site discomfort (pain and/or tenderness). Injection site discomfort was reported as grade 1 by 68 subjects (25%), grade 2 by two subjects (<0.1%) and no grade 3 reactions were reported. Other local reactions (bruising, redness, swelling) had frequencies of less than 3%. The majority of local reactions were grade 1, with only 3 subjects experiencing grade 2 reactions. With the exception of grade 1 injection site discomfort, there were no significant differences in frequencies of local reactions between vaccine groups. The most common solicited systemic reaction following the first immunization was headache in 19 subjects (6.9%), followed by fatigue (4.8%), myalgia (3.3%), nausea/vomiting (1.8%) and fever (1.1%). The frequency of headache was significantly lower ($p < 0.05$ by Fishers exact test) in subjects receiving Advax™ adjuvant (4/137: 2.9%), compared to rHA alone (15/137: 10.9%). There were no other significant differences in frequencies of systemic reactions between vaccine groups and no grade 3 systemic reactions were reported.

After the second immunization the pattern of solicited local reactions was similar to the first, with grade 1 injection site discomfort again being the most common local reaction. Only 5 subjects (1.8%) experienced grade 2 local reactions, with 4/5 (80%) being injection site discomfort. No grade 3 local reactions were reported. The most common systemic reaction was again headache in 10 (3.7%) subjects, followed by fatigue (1.8%) and fever (1.8%). There was again a trend ($p=0.06$) to less post-immunization headaches in groups receiving Advax™ adjuvant (2/135: 1.5%) compared to rHA alone (8/137: 5.8%). There were no significant differences in frequencies of systemic reactions between vaccine groups. Frequencies of unsolicited AE collected throughout the whole study period were not significantly different between vaccine groups. A total of 18 SAE were reported involving 17 individual subjects with none being classed as vaccine-related by the Study Investigator.

DISCUSSION

The 2009 H1N1 pandemic highlighted the need for rapidly scalable influenza vaccine production and presented a unique opportunity to test a new vaccine approach in a real-life pandemic setting. The rHA vaccine was produced and released in less than 12 weeks from initial virus identification. The vaccine was well tolerated and responses were influenced positively by antigen dose and adjuvant and negatively by subject age. This study included a high proportion of elderly, obese and chronic disease subjects, not well represented in other H1N1/2009 trials, which may have negatively impacted on the overall seroprotection rates achieved with the rHA vaccine. The lower vaccine response rates observed in subjects over the age of 50 years have similarly been reported by other H1N1/2009 vaccine studies [26, 27]. The reduced responsiveness in older subjects in our study was improved by higher antigen doses, Advax™ adjuvant and a booster immunization. With all factors optimized (maximum rHA dose, Advax™ adjuvant, and two immunizations), subjects aged over 50 years achieved a seroprotection rate of 61.3%.

On their face, the HI results obtained with the rHA vaccine are lower than results of studies performed with conventional egg-based H1N1/2009 pandemic vaccines, where in most cases a single immunization achieved over 80% seroprotection. For example, in a Chinese study a 15ug dose of inactivated H1N1 in adults 18–60 years achieved 82.1% seroprotection [28] and in a US study a 15 or 30ug dose of inactivated H1N1 vaccine in adults 18–64 year achieved >95% seroprotection [29]. Equally high seroprotection levels were seen in studies of either conventional egg-based or cell culture grown inactivated H1N1/2009 vaccines [26] [28] [30]. This raises the important question of why the rHA vaccine required at least three fold higher antigen doses plus an adjuvant to achieve still relatively modest levels of seroprotection which, except at the highest 45ug HA dose, did not generate HI titers sufficient to meet CHMP/FDA licensing requirements, and even at the highest 45ug dose still only met 2/3 CHMP criteria? This low immunogenicity outcome is reflected in previous studies when recombinant and inactivated seasonal influenza vaccines have been compared head to head, where 45ug dose of rHA was required to produce the same HI titers as 15ug of inactivated HA antigen [17]. Thus, an inherent property of rHA antigen appears to be that it is a third the immunogenicity of an equivalent dose of inactivated virus antigen. The reasons for this difference is not known but may reflect the fact that inactivated vaccines contain many other components including neuraminidase and nuclear proteins, plus viral RNA, that act as inbuilt adjuvants and thereby increase the immunogenicity of inactivated HA antigen [31, 32]. Notably, inactivated influenza vaccines lose their immunogenicity when administered to toll-like receptor (TLR)-7 or MYD88 knockout mice, in which RNA contained in inactivated vaccines is unable to activate the innate immune system and act as an adjuvant [33].

Another surprising finding in our study was the limited boosting effect of the second dose of rHA vaccine. This may partly be because of the short time window between doses, as a longer dose interval of up to 12 months between boosters has previously been shown in the case of hepatitis B vaccines to improve vaccine responses [34]. Alternatively, given the inverse relationship between cellular (Th1) and humoral (Th2) immunity [35], it is possible that the low-responders on HI were instead making a strong T-cell response to the vaccine, which in turn inhibited the antibody response [35]. In future vaccine studies, we plan to also measure anti-influenza T-cell responses to examine this more closely.

Another consideration when trying to compare the study responses to those obtained with inactivated H1N1/2009 vaccines, is that inter-study comparisons based on HI titers are problematic being highly dependent on factors such as the HA antigen and red blood cell species used, and HI assays remain poorly standardized between laboratories [36]. For

example, another study reported a much higher estimate of baseline seroprotection to H1N1 2009 of 32% in the South Australian population compared to our HI assay based estimate of just 9.1% baseline seroprotection, despite the two studies being performed in the same population at the same time [26]. Our estimate of 9.1% baseline seroprotection appears more consistent with reported US, Chinese and European data obtained early in the H1N1/2009 pandemic [27, 37, 38]. Seroprotection rates measured by HI assay may understate the protection achieved with adjuvanted rHA vaccine as, for example, a single dose of Advax™-formulated H5N1 vaccine in a recent ferret study completely protected against H5N1 challenge even when there was no detectable HI titer prior to challenge [23]. Thus, HI titers alone are an imperfect measure of influenza protection. Advax™ adjuvant has been shown to enhance memory CD4 and CD8 T cell vaccine responses, and T cells make an important contribution to protection against influenza [39] [40] [41] [42]. Although our study was not designed as an infection outcome study, it is notable that there was an extremely low rate of late seroconversions between weeks 6 and 26 (3.9%), consistent with a low rate of H1N1/2009 infection in the immunized study subjects during a period when the H1N1/2009 pandemic was at its peak.

There has been considerable debate regarding the benefits and risks of incorporating adjuvants into influenza vaccines. Aluminium adjuvants are unsuitable for influenza vaccines and paradoxically may even reduce immunogenicity[27]. Several squalene oil adjuvanted seasonal influenza vaccines are licensed in Europe for use in the elderly[43]. Following the commencement of our study, studies were undertaken of inactivated H1N1/2009 vaccines together with squalene adjuvants, MF59 or AS03. Squalene adjuvant provided high levels of seroprotection and dose-sparing; for example a 3.75 µg dose of inactivated HA with AS03A adjuvant achieved 94% seroprotection compared to 73% seroprotection with inactivated HA alone [44]. Overall, vaccines containing squalene adjuvants were well tolerated apart from a propensity to increase injection site pain and muscle aches[37]. However, the importance of developing alternative pandemic influenza vaccine adjuvants is highlighted by recent reports of an increased risk of narcolepsy in Scandinavian children immunized with the squalene-adjuvant formulated H1N1/2009 pandemic influenza vaccine (Pandemrix®) [45]. Although the mechanism underlying the association of use of Pandemrix® with narcolepsy is not understood, and may ultimately not implicate the squalene adjuvant used, this issue reinforces the importance of developing a broader range of adjuvants for use in future influenza pandemics.

Advax™ is a novel polysaccharide adjuvant made from particles of delta inulin [20]. In support of previous findings in animal models[21, 23], Advax™ significantly increased the immunogenicity of the rHA vaccine in this study. Given the difficulties of interpreting HI results from different studies we compared, in the same assay, HI titers from the H1N1/2009 vaccine study to convalescent H1N1/2009 patient sera [46]. This confirmed that subjects given the highest dose of rHA plus Advax™ adjuvant achieved comparable HI titers to patients recovered from clinical infection with H1N1/2009.

Enhanced vaccine immunogenicity should not be at the expense of tolerability or safety[47] and in this respect the tolerability and safety profile of Advax™ was reassuring. The lower rate of post-immunization headaches in subjects receiving Advax™ was unexpected, as studies of most adjuvants reveal an increase in headaches[48]. Reduced headaches may relate to adjuvant-induced changes in cytokine production. Immunization headaches are likely to be mediated by inflammatory cytokines, in particular interleukin (IL)-1, as IL-1 serum levels are increased in cluster headaches and IL-1 gene polymorphisms (3953 C/T) are associated with migraine headaches[49, 50]. Unlike pro-inflammatory adjuvants, Advax™ adjuvant does not induce IL-1 gene expression (N. Petrovsky, unpublished data) and this might explain why it doesn't exacerbate post-immunization headaches.

The H1N1/2009 pandemic reinforced the need for innovation in influenza vaccine design and manufacture. Our results confirm the utility and speed of a recombinant vaccine approach to pandemic vaccine production, although there remains a need to optimise the immunogenicity of the recombinant antigen. However, whilst the overall HI data obtained in the current study of recombinant hemagglutinin were modest by reference to CHMP/FDA licensing requirements, this does not necessarily mean that the recombinant vaccine was not effective. Whilst high vaccine-induced HI titers are generally predictive of protection, the converse is not necessarily true, namely low vaccine-induced HI titers do not necessarily predict lack of protection. This fact was clearly demonstrated when ferrets immunized with a H5N1 vaccine formulated with Advax™ adjuvant were completely protected against lethal H5N1 infection despite having no detectable HI titers to H5N1 prior to challenge[23]. What this clearly demonstrates is the urgent need for better assays of immune correlates of influenza vaccine protection to replace traditional HI assays in the licensing of new influenza vaccines. Nevertheless, there is also scope for further enhancement of the rHA approach through further adjustments in antigen and adjuvant dose to help them better meet current CHMP/FDA licensing requirements, and the potential inclusion of recombinant neuraminidase protein to enhance heterotypic immunity [47]. With such strategies to improve immunogenicity in place, a rHA pandemic vaccine may overcome many of the problems of traditional inactivated influenza vaccines and thereby provide benefit in future pandemics.

Acknowledgments

Financial/nonfinancial disclosure: This work was supported by National Institutes of Health [Contracts AI061142 and HHSN272200800039C].

REFERENCES

1. Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. *N Engl J Med*. 2009 Aug 13; 361(7):674–679. [PubMed: 19564633]
2. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. *N Engl J Med*. 2009 Nov 12; 361(20):1935–1944. [PubMed: 19815859]
3. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. *JAMA*. 2009 Nov 4; 302(17):1872–1879. [PubMed: 19822627]
4. Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. *N Engl J Med*. 2009 Nov 12; 361(20):1925–1934. [PubMed: 19815860]
5. Kotsimbos T, Waterer G, Jenkins C, Kelly PM, Cheng A, Hancox RJ, et al. Influenza A/H1N1_09: Australia and New Zealand's winter of discontent. *Am J Respir Crit Care Med*. 2010 Feb 15; 181(4):300–306. [PubMed: 20130145]
6. Wright PF. Vaccine preparedness--are we ready for the next influenza pandemic? *N Engl J Med*. 2008 Jun 12; 358(24):2540–2543. [PubMed: 18550873]
7. Farnsworth A, Cyr TD, Li C, Wang J, Li X. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. *Vaccine*. 2011 Feb 11; 29(8):1529–1533. [PubMed: 21211583]
8. Garcia-Garcia L, Valdespino-Gomez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-Hervet P, et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. *BMJ*. 2009; 339:b3928. [PubMed: 19808768]
9. Kucukosmanoglu E, Yazı D, Yesil O, Akkoc T, Gezer M, Bakirci N, et al. Prevalence of egg sensitization in Turkish infants based on skin prick test. *Allergol Immunopathol (Madr)*. 2008 May-Jun;36(3):141–144. [PubMed: 18680701]

10. Vierk KA, Koehler KM, Fein SB, Street DA. Prevalence of self-reported food allergy in American adults and use of food labels. *J Allergy Clin Immunol.* 2007 Jun; 119(6):1504–1510. [PubMed: 17451802]
11. Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, et al. Immunogenicity, Safety, and Reactogenicity of a Mammalian Cell-Culture-Derived Influenza Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age. *The Pediatric infectious disease journal.* 2012 Feb 1.
12. Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2012 Apr; 54(7):946–954. [PubMed: 22267715]
13. Kida H, Webster RG, Yanagawa R. Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. *Arch Virol.* 1983; 76(2):91–99. [PubMed: 6191738]
14. Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster RG. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. *Virus Res.* 1986 May; 4(3):251–261. [PubMed: 3017016]
15. The Public Health Emergency Medical Countermeasures Enterprise Review. 2010. [Available from: <http://www.phe.gov/preparedness/mcm/enterprisereview>]
16. Nolletti, C. Influenza Vaccine, FluBlok® Purified Recombinant Influenza Hemagglutinin Protein Sciences Corporation. FDA Briefing Document Vaccines and Related Biological Products Advisory Committee Meeting; 2009. p. 1-50.
17. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. *Vaccine.* 2011 Oct 13; 29(44):7733–7739. [PubMed: 21835220]
18. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. *Vaccine.* 1999 May 4; 17(18):2265–2274. [PubMed: 10403594]
19. Treanor JJ, Wilkinson BE, Maseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. *Vaccine.* 2001 Feb 8; 19(13–14):1732–1737. [PubMed: 11166898]
20. Cooper PD, Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 → 1] poly(fructo-furanosyl) alpha-D-glucose polymers. *Glycobiology.* 2011 May; 21(5):595–606. [PubMed: 21147758]
21. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. *J Gen Virol.* 2010 Jun; 91(Pt 6):1407–1417. [PubMed: 20130134]
22. Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. *J Gen Virol.* 2011 Jan; 92(Pt 1):128–140. [PubMed: 21169215]
23. Layton RC, Petrovsky N, Gigliotti AP, Pollock Z, Knight J, Donart N, et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. *Vaccine.* 2011 Jul 4.
24. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine. *Vaccine.* 2006 Mar 15; 24(12):2176–2185. [PubMed: 16310896]
25. Webster, RG.; Cox, N.; Stöhr, K. WHO Manual on Animal Influenza Diagnosis and Surveillance (WHO/CDS/CSR/NCS/2002.5. 2002. Rev. 1:p37- 9.
26. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. *N Engl J Med.* 2009 Dec 17; 361(25):2405–2413. [PubMed: 19745216]

27. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. *N Engl J Med*. 2009 Dec 17; 361(25):2414–2423. [PubMed: 19846844]
28. Sun F, Zhang Y, Tian D, Zheng M, Liu L, Zhang R, et al. Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population--a practical observation. *Vaccine*. 2011 Sep 2; 29(38):6527–6531. [PubMed: 21767595]
29. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. *Lancet*. 2010 Jan 2; 375(9708):41–48. [PubMed: 20018365]
30. Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. *J Infect Dis*. 2010 Nov 1; 202(9):1327–1337. [PubMed: 20874515]
31. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. *Influenza Other Respi Viruses*. 2008 Mar; 2(2):41–51. [PubMed: 19453471]
32. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. *PLoS Pathog*. 2008; 4(8):e1000138. [PubMed: 18769719]
33. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. *J Immunol*. 2007 Oct 1; 179(7):4711–4720. [PubMed: 17878370]
34. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. *J Infect Dis*. 1989 Nov; 160(5):766–769. [PubMed: 2530289]
35. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol*. 1986 Apr 1; 136(7):2348–2357. [PubMed: 2419430]
36. Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. *Vaccine*. 2007 May 16; 25(20):4056–4063. [PubMed: 17412461]
37. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. *N Engl J Med*. 2009 Dec 17; 361(25):2424–2435. [PubMed: 19745215]
38. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N Engl J Med*. 2009 Nov 12; 361(20):1945–1952. [PubMed: 19745214]
39. Webster RG, Askonas BA. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. *Eur J Immunol*. 1980 May; 10(5):396–401. [PubMed: 6967815]
40. Fu TM, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. *J Virol*. 1997 Apr; 71(4):2715–2721. [PubMed: 9060624]
41. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. *J Immunol*. 1998 Jan 1; 160(1):322–327. [PubMed: 9551987]
42. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. *Nat Med*. 2012 Feb; 18(2):274–280. [PubMed: 22286307]
43. Petrovsky N, Ross TM. Challenges in improving influenza vaccine protection in the elderly. *Expert Rev Vaccines*. 2011 Jan; 10(1):7–11. [PubMed: 21162614]
44. Roman F, Clement F, Dewe W, Walravens K, Maes C, Willekens J, et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. *Clin Vaccine Immunol*. 2011 May; 18(5):835–843. [PubMed: 21450978]

45. Nohynek H, Jokinen J, Partinen M, Vaarala O, et al. AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland. *PLoS ONE*. 2012; 7(3):e33536. [PubMed: 22470453]
46. Tan S, Gordon DL, Honda-Okubo Y, Petrovsky N, Phillips P, Huddleston S, et al. Serological responses following influenza A H1N1 2009 infection in adults. *J Infect*. 2011 May; 62(5):388–393. [PubMed: 21420426]
47. Johansson BE, Brett IC. Changing perspective on immunization against influenza. *Vaccine*. 2007 Apr 20; 25(16):3062–3065. [PubMed: 17276554]
48. Precioso AR, Miraglia JL, Campos LM, Goulart AC, Timenetsky Mdo C, Cardoso MR, et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. *Vaccine*. 2011 Nov 8; 29(48):8974–8981. [PubMed: 21945258]
49. Martelletti P, Granata M, Giacobazzo M. Serum interleukin-1 beta is increased in cluster headache. *Cephalalgia*. 1993 Oct; 13(5):343–345. discussion 07-8. [PubMed: 7694804]
50. Rainero I, Pinessi L, Salani G, Valfre W, Rivoiro C, Savi L, et al. A polymorphism in the interleukin-1alpha gene influences the clinical features of migraine. *Headache*. 2002 May; 42(5):337–340. [PubMed: 12047332]

Highlights

- Randomized clinical trial of a novel adjuvanted H1N1/2009 pandemic influenza vaccine
- Reports first pandemic use of a vaccine based on recombinant hemagglutinin
- The recombinant vaccine was produced within 12 weeks of the pandemic
- Advax™, a novel polysaccharide adjuvant, significantly improved vaccine responses

Figure 1. Subject Randomisation Schedule

Footnote (of Figure 1):

¹ Number of subjects providing blood samples at baseline and 3 weeks post-vaccination

² Total of 7 subjects did not have week 3 bloods taken. Reasons for missing samples (number of individuals giving these reasons in brackets): work/other commitments (4); non study-related health issue (1); personal reasons (1); problems giving blood (1)

³ Total of 3 subjects did not have week 6 bloods taken: work/other commitments (1), non studyrelated health issue (1), lost to follow up (1).

⁴ Total of 15 subjects did not have week 26 bloods taken: work/other commitments (2), personal reasons (2), non study-related health issue (1), deceased (1), withdrawal consent (2), lost to follow up (7).

Table 1
Baseline subject characteristics (efficacy population) according to vaccine dose and adjuvant

	H1N1/2009 dose										
	rHA – 3ug			rHA – 11ug		rHA – 45ug					
	All subjects	Non- adjuvanted	Adjuvanted	Non- Adjuvanted	Adjuvanted	Non- adjuvanted	Adjuvanted	Between group comparison			
	n=274	n=46	n=47	n=46	n=43	n=46	n=46	p-value ^f			
Age, median (IQR)	52 (44–60)	51.5 (42–60)	50 (39–59)	51 (44–62)	50 (45–60)	53 (43–60)	54 (45–63)	0.33			
Gender											
Males, n (%)	126 (46.0)	20 (43.5)	25 (53.2)	21 (45.7)	21 (48.8)	21 (45.7)	18 (39.1)	0.83			
Females, n (%)	148 (54.0)	26 (56.5)	22 (46.8)	25 (54.3)	22 (51.2)	25 (54.3)	28 (60.9)				
Received seasonal flu vaccine, n (%)											
In 2009	195 (71.2)	33 (71.7)	32 (68.1)	29 (63.0)	31 (72.1)	35 (76.1)	35 (76.1)	0.73			
Within last 3 years	223 (81.4)	38 (82.6)	37 (78.7)	36 (78.3)	36 (83.7)	38 (82.6)	38 (82.6)	0.98			
BMI, n (%)											
< 25	75 (27.4)	15 (32.6)	12 (25.5)	11 (23.9)	13 (30.2)	13 (28.3)	11 (23.9)				
25 to 30	98 (35.8)	14 (30.4)	19 (40.4)	15 (32.6)	14 (32.6)	16 (34.8)	20 (43.5)	0.96			
Above 30	101 (36.9)	17 (37.0)	16 (34.0)	20 (43.5)	16 (37.2)	17 (37.0)	15 (32.6)				
Race, n (%)											
Caucasian	264 (96.4)	45 (97.8)	45 (95.7)	44 (95.6)	41 (95.4)	44 (95.6)	45 (95.6)	0.97			
Other (Asian/Lebanese)	10 (3.6)	1 (2.2)	2 (4.3)	2 (4.4)	2 (4.6)	2 (4.4)	1 (2.2)				
Chronic disease ² , n (%)	150 (54.7)	23 (50.0)	27 (57.4)	23 (50.0)	24 (55.8)	22 (47.8)	31 (57.4)	0.42			

¹ Difference between groups using ANOVA, median test or chi-square test as appropriate.

² Receiving medication for long-term chronic disease (excludes hay fever).

Table 2
A. Effects of dose, adjuvant and age on GMT, seropositivity and seroconversion at week 3 post-immunization

rHA dose	Adjuvant	Age	n	Baseline GMT (% 95% CI)	Baseline seroprotection (% 95% CI)	Week 3 GMT (95% CI)	Week 3 Seroprotection (% 95% CI)	Week 3 Seroconversion (% 95% CI)	Week 3 GMT (Fold change)
3 ug	No	18-49	22	15.1 (10.9-20.8)	18.2 (5.2-40.3)	24.2 (15.9-36.6)	31.8 (13.9-54.9)	18.2 (5.2-40.3)	1.6 (1.2-2.2)
	No	50 +	24	11.2 (9.7-12.9)	4.2 (0.1-21.1)	16.3 (11.4-23.4)	25.0 (9.8-46.7)	20.8 (7.1-42.2)	1.5 (1.1-2.0)
	No	All ages	46	12.9 (10.9-15.3)	10.9 (3.6-23.6)	19.7 (15.1-25.8)	28.3 (16.0-43.5)	19.6 (9.4-33.9)	1.5 (1.2-1.9)
	Yes	18-49	22	12.9 (10.5-15.8)	9.1 (1.1-29.2)	26.6 (18.7-37.7)	54.5 (32.2-75.6)	36.4 (17.2-59.3)	2.1 (1.6-2.7)
	Yes	50 +	25	12.8 (10.2-16.2)	12.0 (2.5-31.2)	22.3 (14.7-34.0)	40.0 (21.1-61.3)	24.0 (9.4-45.1)	1.7 (1.2-2.5)
	Yes	All ages	47	12.8 (11.1-14.9)	10.6 (3.5-23.1)	24.2 (18.5-31.7)	46.8 (32.1-61.9)	29.8 (17.3-44.9)	1.9 (1.5-2.4)
11 ug	No	18-49	19	14.9 (9.9-22.4)	10.5 (1.3-33.1)	44.6 (24.7-80.7)	63.2 (38.4-83.7)	52.6 (28.9-75.6)	3.0 (1.8-5.0)
	No	50 +	27	11.7 (9.4-14.5)	3.7 (0.1-19.0)	18.0 (10.9-30.0)	11.1 (2.4-29.2)	11.1 (2.4-29.2)	1.5 (1.1-2.2)
	No	All ages	46	12.9 (10.5-15.9)	6.5 (1.4-17.9)	26.2 (17.7-38.9)	32.6 (19.5-48.0)	28.3 (16.0-43.5)	2.0 (1.5-2.8)
	Yes	18-49	21	11.8 (9.7-14.4)	9.5 (1.2-30.4)	25.2 (17.0-37.2)	38.1 (18.1-61.6)	23.8 (8.2-47.2)	2.1 (1.5-3.0)
	Yes	50 +	22	12.9 (9.5-17.5)	13.6 (2.9-34.9)	25.7 (15.2-43.5)	40.9 (20.7-63.6)	27.3 (10.7-50.2)	2.0 (1.3-3.1)
	Yes	All ages	43	12.3 (10.3-14.7)	11.6 (3.9-25.1)	25.5 (18.6-34.9)	39.5 (25.0-55.6)	25.6 (13.5-41.2)	2.1 (1.6-2.7)
45 ug	No	18-49	19	14.4 (8.8-23.5)	15.8 (3.4-39.6)	48.0 (23.6-97.8)	57.9 (33.5-79.7)	42.1 (20.3-66.5)	3.3 (1.8-6.3)
	No	50 +	27	10.8 (9.9-11.8)	0.0 (0.0-12.8)	23.3 (14.8-36.9)	29.6 (13.8-50.2)	29.6 (13.8-50.2)	2.2 (1.5-3.2)
	No	All ages	46	12.2 (9.9-14.9)	6.5 (1.4-17.9)	31.4 (21.2-46.7)	41.3 (27.0-56.8)	34.8 (21.4-50.2)	2.6 (1.8-3.7)
	Yes	18-49	15	11.5 (9.3-14.2)	6.7 (0.2-31.9)	127.0 (51.5-313.0)	80.0 (51.9-95.7)	73.3 (44.9-92.2)	11.1 (4.6-26.4)
	Yes	50 +	31	12.2 (10.1-14.8)	9.7 (2.0-25.8)	37.4 (23.1-60.7)	48.4 (30.2-66.9)	45.2 (27.3-64.0)	3.1 (2.0-4.7)
	Yes	All ages	46	12.0 (10.4-13.8)	8.7 (2.4-20.8)	55.7 (35.4-87.6)	58.7 (43.2-73.0)	54.3 (39.0-69.1)	4.7 (3.0-7.1)
All subjects			274	12.5 (11.7-13.4)	9.1 (6.0-13.2)	28.7 (24.8-33.2)	41.2 (35.4-47.3)	32.1 (26.6-38.0)	2.3 (2-2.6)

B. Effects of dose, adjuvant and age on GMT, seropositivity and seroconversion at week 3 post-immunization

Week 3 Geometric mean titre	Ratio of predicted geometric means $\bar{I}$ (95% CI)	p-value ²
Dose		

B: Effects of dose, adjuvant and age on GMT, seropositivity and seroconversion at week 3 post-immunization

Week 3 Geometric mean titre		Ratio of predicted geometric means I (95% CI)	p-value ²
3		1.00	
11		1.2 (0.9–1.6)	0.21
45		2.1 (1.6–2.9)	<0.001
Adjuvant			
No adjuvant		1.00	
Advax™		1.3 (1.0–1.7)	0.026
Age			
50 years or older		1.00	
Less than 50 years old		1.6 (1.2–2.0)	<0.001
Week 3 seroprotection		Odds ratio (95% CI)	p-value ¹
Dose			
3		1.00	
11		0.9 (0.5–1.8)	0.84
45		2.0 (1.1–3.6)	0.03
Adjuvant			
No adjuvant		1.00	
Advax™		1.9 (1.2–3.2)	0.01
Age			
50 years or older		1.00	
Less than 50 years old		2.8 (1.7–4.6)	<0.001
Week 3 seroconversion		Odds ratio (95% CI)	p-value ¹
Dose			
3		1.00	
11		1.1 (0.6–2.3)	0.70
45		2.8 (1.5–5.2)	0.002
Adjuvant			
No adjuvant		1.00	
Advax™		1.6 (0.9–2.7)	0.08

B: Effects of dose, adjuvant and age on GMT, seropositivity and seroconversion at week 3 post-immunization

Week 3 Geometric mean titre	Ratio of predicted geometric means ¹ (95% CI)	p-value ²
Age	0.003	
50 years or older	0.003	
Less than 50 years old	2.3 (1.3–3.9)	0.003

C. Vaccine HI responses in 18–60 year olds by CHMP criteria

18–60 years	Seroprotection	>70%	Seroconversion	>40%	Fold GMT increase	>2.5
3 ug		35.1	N	24.3 (11.8–41.2)	N	1.7 (1.3–2.2)
3 ug + Advax		47.5	N	32.5 (18.6–49.1)	N	2.0 (1.6–2.6)
11 ug		40.6	N	34.4 (18.6–53.2)	N	2.1 (1.5–3.0)
11 ug + Advax		45.5	N	33.3 (18.0–51.8)	N	2.5 (1.8–3.4)
45 ug		48.6	N	40.0 (23.9–57.9)	Y	2.9 (1.8–4.5)
45 ug + Advax		63.6	N	57.6 (39.2–74.5)	Y	5.8 (3.4–10.0)

D. Vaccine HI responses in >60 year olds by CHMP criteria

60+ years	Seroprotection	>60%	Seroconversion	>30%	Fold GMT increase	>2.0
3 ug		0	N	0	N	1
3 ug + Advax		42.9	N	14.3	N	1.3
11 ug		14.3	N	14.3	N	1.9
11 ug + Advax		20	N	0	N	1.1
45 ug		18.2	N	18.2	N	1.9
45 ug + Advax		46.2	N	46.2	Y	2.6

¹After adjustment for baseline (week 0) titre.

²Using generalized linear models with main effects of dose, adjuvant and age.

Table 3

A. Study week 6 response (3 weeks post-2nd immunization). Study week 3 GMT responses are included for comparison.

rHA dose	Adjuvant	Age	n	Week 3 (1 dose) GMT Value (95% CI)	Week 6 (2 dose) GMT Value (95% CI)	Week 6 Seroprotection %, (95% CI)	Week 6 Seroconversion %, (95% CI)	Wk6 to Wk3 GMT fold change
3 ug	No	18-49	22	24.2 (15.9-36.6)	22.0 (15.8-30.7)	31.8 (13.9-54.9)	22.7 (7.8-45.4)	0.9 (0.6-1.3)
	No	50 +	23	16.3 (11.4-23.4)	15.7 (10.5-23.4)	12.5 (2.7-32.4)	12.5 (2.7-32.4)	1.0 (0.8-1.2)
	No	All ages	45	19.7 (15.1-25.8)	18.5 (14.3-23.9)	22.2 (11.2-37.1)	17.8 (8-32.1)	0.9 (0.8-1.1)
	Yes	18-49	21	26.0 (18.1-37.6)	36.2 (22.9-57.4)	59.1 (36.4-79.3)	54.5 (32.2-75.6)	1.4 (1.0-1.8)
	Yes	50 +	25	22.3 (14.7-34.0)	28.7 (18.5-44.4)	48.0 (27.8-68.7)	36.0 (18.0-57.5)	1.3 (1.0-1.6)
	Yes	All ages	46	24.0 (18.2-31.5)	31.9 (23.5-43.4)	54.3 (39.0-69.1)	45.7 (30.9-61.0)	1.3 (1.1-1.6)
11 ug	No	18-49	19	44.6 (24.7-80.7)	48.0 (26.4-87.3)	73.7 (48.8-90.9)	57.9 (33.5-79.7)	1.1 (0.8-1.4)
	No	50 +	27	18.0 (10.9-30.0)	25.9 (15.3-43.6)	33.3 (16.5-54.0)	33.3 (16.5-54.0)	1.4 (1.1-1.8)
	No	All ages	46	26.2 (17.7-38.9)	33.4 (22.6-49.3)	50.0 (34.9-65.1)	43.5 (28.9-58.9)	1.3 (1.1-1.5)
	Yes	18-49	21	25.2 (17-37.2)	44.2 (29.9-65.2)	71.4 (47.8-88.7)	61.9 (38.4-81.9)	1.8 (1.4-2.2)
	Yes	50 +	22	25.2 (14.5-43.7)	28.3 (17.6-45.3)	45.5 (24.4-67.8)	36.4 (17.2-59.3)	1.1 (0.9-1.4)
	Yes	All ages	43	25.2 (18.3-34.8)	35.2 (26.0-47.6)	58.1 (42.1-73.0)	48.8 (33.3-64.5)	1.4 (1.1-1.7)
45 ug	No	18-49	18	48.5 (22.8-103.2)	68.6 (36.1-130.4)	63.2 (38.4-83.7)	47.4 (24.4-71.1)	1.4 (1.1-1.8)
	No	50 +	27	23.3 (14.8-36.9)	25.2 (16.6-38.2)	37.0 (19.4-57.6)	37.0 (19.4-57.6)	1.1 (0.9-1.3)
	No	All ages	45	31.3 (20.9-46.9)	37.6 (25.9-54.6)	48.9 (33.7-64.2)	42.2 (27.7-57.8)	1.2 (1-1.4)
	Yes	18-49	15	127.0 (51.5-313)	139.3 (60.4-321.3)	80.0 (51.9-95.7)	73.3 (44.9-92.2)	1.1 (0.7-1.6)
	Yes	50 +	31	37.4 (23.1-60.7)	46.8 (29.3-74.7)	61.3 (42.2-78.2)	58.1 (39.1-75.5)	1.3 (1.0-1.5)
	Yes	All ages	46	55.7 (35.4-87.6)	66.8 (43.6-102.2)	67.4 (52.0-80.5)	63.0 (47.5-76.8)	1.2 (1.0-1.4)
All subjects			271	28.6 (24.7-33.2)	34.8 (30.1-40.2)	50.2 (44.1-56.3)	43.5 (37.6-49.7)	1.2 (1.1-1.3)

B: Effects of dose, adjuvant and age on GMT, seropositivity and seroconversion at Week 6 (3 weeks post 2nd immunization).

Week 6 Geometric mean titre	Ratio of predicted Geometric means [†] (95% CI)	p-value ²
Dose		

B: Effects of dose, adjuvant and age on GMT, seropositivity and seroconversion at Week 6 (3 weeks post 2 nd immunization).			
Week 6 Geometric mean titre	Ratio of predicted Geometric means ^I (95% CI)	p-value ²	
3	1.00		
11	1.4 (1.0–1.9)	0.02	
45	2.3 (1.7–3.1)	<0.001	
Adjuvant			
No adjuvant	1.00		
Advax™	1.5 (1.2–1.9)	0.001	
Age			
50 years or older	1.00		
Less than 50 years old	1.7 (1.3–2.2)	<0.001	
Week 6 seroprotection	Odds ratio (95% CI)	p-value ^I	
Dose			
3	1.00		
11	2.1 (1.1–3.9)	0.02	
45	2.9 (1.5–5.4)	0.001	
Adjuvant			
No adjuvant	1.00		
Advax™	2.5 (1.5–4.2)	0.001	
Age			
50 years or older	1.00		
Less than 50 years old	3.2 (1.9–5.5)	<0.001	
Week 6 seroconversion	Odds ratio (95% CI)	p-value ^I	
Dose			
3	1.00		
11	2.0 (1.0–3.7)	0.04	
45	2.9 (1.5–5.5)	0.001	
Adjuvant			
No adjuvant	1.00		

B: Effects of dose, adjuvant and age on GMT, seropositivity and seroconversion at Week 6 (3 weeks post 2 nd immunization).		
Week 6 Geometric mean titre	Ratio of predicted Geometric means ¹ (95% CI)	p-value ²
Advax TM	2.3 (1.4–3.8)	0.002
Age		
50 years or older	1.00	
Less than 50 years old	2.5 (1.5–4.2)	0.001

¹ After adjustment for baseline (week 0) titre.

² Using generalized linear models with main effects of dose, age and adjuvant

Table 4

A. Durability of response at study week 26, 23 weeks after 2nd immunization

Dose	Adjuvant	Age group	n	Week 26 GMT value (95% CI)	Week 6 GMT value (95% CI)	Week 26 Seroconversion % (95% CI)	Week 26 Seroconversion % (95% CI)	Wk 26 over Wk 6 GMT fold change
3 ug	No	18-49	22	22.1 (16.3-29.9)	22.0(15.8-30.7)	31.8 (13.9-54.9)	18.2 (5.2-40.3)	1.0 (0.8-1.2)
	No	50 +	24	17.7 (12.5-25.1)	15.7(10.5-23.4)	8.3 (1-27)	8.3 (1-27)	1.1 (0.9-1.4)
	No	All ages	44	19.7 (15.7-24.7)	18.5(14.3-23.9)	20.5 (9.8-35.3)	13.0 (4.9-26.3)	1.1 (0.9-1.2)
11 ug	Yes	18-49	22	45.9 (32.1-65.8)	36.2(22.9-57.4)	68.2 (45.1-86.1)	59.1 (36.4-79.3)	1.3 (0.9-1.7)
	Yes	50 +	25	25.5 (16.9-38.4)	28.7(18.5-44.4)	40.0 (21.1-61.3)	28.0 (12.1-49.4)	0.9 (0.7-1.2)
	Yes	All ages	43	33.5 (25.3-44.3)	31.9(23.5-43.4)	58.1 (42.1-73)	42.6 (28.3-57.8)	1.0 (0.8-1.3)
45 ug	No	18-49	19	41.7 (25.4-68.4)	48.0(26.4-87.3)	52.6 (28.9-75.6)	42.1 (20.3-66.5)	0.9 (0.6-1.2)
	No	50 +	27	25.7 (16.9-39.1)	25.9(15.3-43.6)	33.3 (16.5-54)	33.3 (16.5-54)	1.0 (0.8-1.3)
	No	All ages	42	31.2 (22.8-42.8)	33.4(22.6-49.3)	45.2 (29.8-61.3)	37.0 (23.2-52.5)	0.9 (0.8-1.1)
45 ug	Yes	18-49	21	44.4 (31.2-63.2)	44.2(29.9-65.2)	71.4 (47.8-88.7)	66.7 (43-85.4)	1.0 (0.8-1.2)
	Yes	50 +	22	28.8 (18.9-43.7)	28.3(17.6-45.3)	50.0 (28.2-71.8)	36.4 (17.2-59.3)	1.0 (0.9-1.2)
	Yes	All ages	41	35.5 (27.1-46.6)	35.2(26-47.6)	63.4 (46.9-77.9)	51.2 (35.5-66.7)	1.0 (0.9-1.2)
All	No	18-49	19	56.6 (35.7-89.8)	68.6(36.1-130.4)	78.9 (54.4-93.9)	63.2 (38.4-83.7)	0.8 (0.6-1.2)
	No	50 +	27	22.3 (15.9-31.3)	25.2(16.6-38.2)	25.9 (11.1-46.3)	25.9 (11.1-46.3)	0.9 (0.7-1.1)
	No	All ages	43	33.0 (24.4-44.5)	37.6(25.9-54.6)	51.2 (35.5-66.7)	41.3 (27-56.8)	0.9 (0.7-1.1)
All	Yes	18-49	15	105.6 (57.2-194.7)	139.3(60.4-321.3)	80.0 (51.9-95.7)	73.3 (44.9-92.2)	0.8 (0.5-1.1)
	Yes	50 +	31	38.1 (25.7-56.4)	46.8(29.3-74.7)	51.6 (33.1-69.8)	48.4 (30.2-66.9)	0.8 (0.7-1)
	Yes	All ages	43	54.3 (38.2-77.3)	66.8(43.6-102.2)	65.1 (49.1-79)	56.5 (41.1-71.1)	0.8 (0.7-1)
			256	33.0 (29.2-37.3)	34.8(30.1-40.2)	50.4 (44.1-56.7)	43.0 (36.8-49.3)	1.0 (0.9-1)

B: Effects of dose, adjuvant and age on GMT, seropositivity, and seroconversion at week 26 (23 weeks post 2nd immunization)

Week 26 Geometric mean titre	Ratio of predicted Geometric means ¹ (95% CI)	p-value ²
Dose		

B: Effects of dose, adjuvant and age on GMT, seropositivity, and seroconversion at week 26 (23 weeks post 2 nd immunization)			
Week 26 Geometric mean titre	Ratio of predicted Geometric means ^I (95% CI)	p-value ²	
3	1.00		
11	1.3 (1.0–1.7)	0.031	
45	1.8 (1.4–2.3)	<0.001	
Adjuvant			
No adjuvant	1.00		
Advax™	1.5 (1.2–1.8)	<0.001	
Age			
50 years or older	1.00		
Less than 50 years old	1.7 (1.4–2.1)	<0.001	
Week 26 seroprotection	Odds ratio (95% CI)	p-value ^I	
Dose			
3	1.00		
11	2.1 (1.1–4.1)	0.03	
45	2.9 (1.5–5.6)	0.002	
Adjuvant			
No adjuvant	1.00		
Advax™	3.0 (1.7–5.2)	<0.001	
Age			
50 years or older	1.00		
Less than 50 years old	4.1 (2.3–7.2)	<0.001	
Week 26 seroconversion	Odds ratio (95% CI)	p-value ^I	
Dose			
3	1.00		
11	2.3 (1.2–4.5)	0.015	
45	3.3 (1.7–6.5)	0.001	
Adjuvant			
No adjuvant	1.00		

B: Effects of dose, adjuvant and age on GMT, seropositivity, and seroconversion at week 26 (23 weeks post 2 nd immunization)		
Week 26 Geometric mean titre	Ratio of predicted Geometric means ¹ (95% CI)	p-value ²
Advax TM	2.7 (1.6–4.6)	<0.001
Age		
50 years or older	1.00	
Less than 50 years old	3.3 (1.9–5.7)	<0.001

¹ After adjustment for baseline (week 0) titre.

² Using generalized linear models with main effects of dose, age and adjuvant.

Table 5

Seasonal influenza response at week three following rH1 2009 vaccination. Number of subjects who developed HI titer 40 and 4 fold increase in HI titer according to vaccine dose, adjuvant, baseline seasonal influenza titer and age group

	rHA - 3µg			rHA - 11µg		rHA - 45µg		
	Non- adjuvanted n=46	Adjuvanted n=47	Non-adjuvanted n=46	Adjuvanted n=43	Non-adjuvanted n=46	Adjuvanted n=46	All groups	Effect of age (χ ² , df) p-value
Baseline HI <40								
<50 years	1/5	2/10	0/8	0/9	0/5	2/4	5/41	(4.16, 1df)
>50 years	0/9	1/13	0/13	1/17	0/10	0/12	2/74	p=0.04
Baseline HI 40								
<50 years	0/17	0/12	1/11	1/12	2/14	2/11	6/77	(4.08, 1df)
>50 years	0/15	0/12	0/14	0/5	0/17	1/19	1/82	p=0.043
All subjects								
<50 years	1/22	1/21	1/17	1/20	2/18	4/11	11/118	(7.59, 1df)
>50 years	0/24	1/24	0/27	1/21	0/27	1/30	3/156	p=0.006